For the second time this month, there's promising news from a COVID-19 vaccine candidate: Moderna said Monday its shots provide strong protection, a dash of hope against the grim backdrop of coronavirus surges in the U.S. and around the world.

Moderna said its vaccine appears to be 94.5% effective, according to preliminary data from the company’s still ongoing study. A week ago, competitor Pfizer Inc. announced its own COVID-19 vaccine appeared similarly effective — news that puts both companies on track to seek permission within weeks for emergency use in the U.S.

Dr. Stephen Hoge, Moderna’s president, welcomed the “really important milestone” but said having similar results from two different companies is what’s most reassuring.

“That should give us all hope that actually a vaccine is going to be able to stop this pandemic and hopefully get us back to our lives,” Hoge told The Associated Press.

“It won’t be Moderna alone that solves this problem. It’s going to require many vaccines” to meet the global demand, he added.

A vaccine can’t come fast enough, as virus cases topped 11 million in the U.S. over the weekend — 1 million of them recorded in just the past week. The pandemic has killed more than 1.3 million people worldwide, more than 245,000 of them in the U.S.

Still, if the Food and Drug Administration allows emergency use of Moderna’s or Pfizer’s candidates, there will be limited, rationed supplies before the end of the year. Both require people to get two shots, several weeks apart. Moderna expects to have about 20 million doses, earmarked for the U.S., by the end of 2020. Pfizer and its German partner BioNTech expect to have about 50 million doses globally by year’s end.

Moderna’s vaccine, created with the National Institutes of Health, is being studied in 30,000 volunteers who received either the real vaccination or a dummy shot. On Sunday, an independent monitoring board broke the code to examine 95 infections that were recorded starting two weeks after volunteers' second dose — and discovered all but five illnesses occurred in participants who got the placebo.

The study is continuing, and Moderna acknowledged the protection rate might change as more COVID-19 infections are detected and added to the calculations. Also, it’s too soon to know how long protection lasts. Both cautions apply to Pfizer’s vaccine as well.

But Moderna’s independent monitors reported some additional, promising tidbits: All 11 severe COVID-19 cases were among placebo recipients, and there were no significant safety concerns.

The main side effects were fatigue, muscle aches and injection-site pain after the vaccine’s second dose, at rates that Hoge characterized as more common than with flu shots but on par with others such as shingles vaccine.

Moderna shares rocketed higher on the announcement and appeared to be headed for an all-time high Monday. The Cambridge, Massachusetts, company's vaccine is among 11 candidates in late-stage testing around the world, four of them in huge studies in the U.S.

Both Moderna's shots and the Pfizer-BioNTech candidate are so-called mRNA vaccines, a brand-new technology. They aren’t made with the coronavirus itself, meaning there’s no chance anyone could catch it from the shots. Instead, the vaccine contains a piece of genetic code that trains the immune system to recognize the spiked protein on the surface of the virus.

The strong results were a surprise. Scientists have warned for months that any COVID-19 shot may be only as good as flu vaccines, which are about 50% effective.

Another steep challenge: distributing doses that must be kept very cold. Both the Moderna and Pfizer shots are frozen but at different temperatures. Moderna announced Monday that once thawed, its doses can last longer in a refrigerator than initially thought, up to 30 days. Pfizer's shots require long-term storage at ultra-cold temperatures.

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Share:
More In Science
Beyond Meat Expands McDonald's Deal As Fast Food Reign Continues
Plant-based meat giant Beyond Meat's reign over the fast food world continues, as McDonald's announced that it is expanding its test of Beyond's McPlant burger, to nearly 600 restaurants, an increase from the eight that it's been testing in since November. This comes less than two weeks after Beyond Fried Chicken made its nationwide debut at KFC restaurants, the first time that plant based chicken has been widely distributed in a fast food capacity. Arun Sundaram, Senior Equity Analyst at CFRA Research explains why these latest collaborations may be proof that Beyond Meat products could slowly be becoming an unlikely staple in the fast food and chain restaurant world as consumers opt for more healthy food options.
BD Veritor Hopes to Take 'Guesswork' Out With Smartphone-Enabled COVID Test
BD Veritor is a variation of the at-home COVID test that uses a smartphone to interpret the results. The test is taken via a nose swab test strip that is then scanned by your phone’s camera with the result clearly displayed as positive or negative. James Walker, vice president of integrated diagnostics USA for BD, joined Cheddar to discuss how the test hopefully takes the "guesswork out of testing." Walker also went into what BD is doing to deal with the surging demand for at-home tests amid the omicron spread. "While we don't disclose how much we produce, we have capacity to manufacture up to 12 million rapid antigen tests per month and are delivering on our commitments to distributors and retailers," he said.
Robotics for Eyelash Extensions; Innovation in Food Tech
On this episode of Cheddar Innovates: Sidechef CEO breaks down how it's building a platform to make recipe shopping easy; Luum CEO explains the process of having a robot put on eyelash extensions; A look at Curiosity Stream's new original series, 'Evolve.'
Moderna's Chief Medical Officer on Omicron Booster Trial, Annual Shots
Moderna launched a clinical trial of a COVID-19 booster shot specifically targeting the omicron variant. The first participant has already received a dose, and Moderna expects to enroll about 600 adults total, split between two groups. In the first group, participants will have previously received two doses of the Moderna vaccine, and in the second, participants will have received its booster. Dr. Paul Burton, chief medical officer at Moderna, joined Cheddar’s Opening Bell to discuss the trial, yearly boosters, and what lies ahead for the company.
Beijing Pledges to Host 'Low Carbon' Olympic Games
With the 2022 Beijing Winter Olympics right around the corner, experts are warning that climate change is threatening not only the event but also the future of snow sports. Despite being the world's top polluter, China is hoping to use the event to demonstrate the country's commitment to fighting climate change, and pledging to host a "low carbon" games. Xubin Zeng, professor of hydrology and atmospheric sciences at the University of Arizona, joins Cheddar News.
Study Finds Payments for Low-Income Mothers May Impact Infants' Brains
New research is suggesting that giving extra cash to low-income mothers can actually influence the brain development of their infants. These findings provide the first rigorous evidence of how payments and monetary support can affect children in the early years of life. Authors of the study, Nathan Fox, professor in the department of human development at the University of Maryland, and Sonya Troller-Renfree, postdoctoral research associate at Teachers College at Columbia University, join Cheddar News to discuss.
Load More